15:34:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.

Kalender

2022-02-15 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2021-01-04 Extra Bolagsstämma 2021
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2020-03-31 Bokslutskommuniké 2019
2019-12-31 Kvartalsrapport 2019-Q3
2019-12-20 Extra Bolagsstämma 2019
2019-09-30 Kvartalsrapport 2019-Q2
2019-06-30 Kvartalsrapport 2019-Q1
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2019-03-31 Bokslutskommuniké 2018
2018-12-31 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-02 Split SOFTX 1:50
2018-06-07 Kvartalsrapport 2018-Q1
2021-02-24 08:30:00
Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 16 February 2021 regarding the commencement of the
subscription period in the planned subsequent offering and parallel employee
offering, both consisting of an issuance of up to 181,818 new shares in the
Company.

Primary insider Geir Almås, CEO, has committed to subscribe for NOK 1 999 800 in
the Employee Offering.
Primary insider Melvin Teigen, Chairman of the Board, has committed to subscribe
for NOK 550 000 in the Employee Offering.
Primary insider Glenn Gundersen, Medical Director, has committed to subscribe
for NOK 250 250 in the Employee Offering.
Primary insider Hans Petter Grette, Business Development & Marketing Director,
has committed to subscribe for NOK 400 840 in the Employee Offering.
Primary insider Kristine Rød, Finance Manager, has committed to subscribe for
NOK 200 000 in the Employee Offering.

The subscription period for the Company's employees, the Board of Directors and
certain invited hired external consultants expire at 16:30 hours (CET) on 24
February 2021. By 23 February 2021 there has been made subscriptions by primary
insiders for MNOK 3 400. The Employee Offering is conditional upon a final
approval and allocation from the Board of Directors around 24 February 2021 and
issued under a board authorization granted by the Company's general meeting held
on 4 January 2021. The shares in the Subsequent Offering will be allocated by
the Board of Directors and will be issued in accordance with the resolution made
by the Company's general meeting held on 4 January 2021.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth)
is a Norwegian MedTech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR), biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com